Science is moving fast across nearly every major discipline right now. From nuclear fusion milestones to gene-editing therapies already treating patients, the past two years have produced breakthroughs that would have seemed implausible a decade ago. Here’s a field-by-field look at the developments reshaping what’s possible.
Nuclear Fusion Hit a Major Milestone
The National Ignition Facility (NIF) in California has now achieved fusion ignition 10 times, with a record energy output of 8.6 megajoules from just 2.08 megajoules of laser energy delivered to the target. That’s a target gain of 4.13, meaning the fusion reaction produced more than four times the energy that the lasers put in. The first ignition happened in December 2022, producing 3.15 megajoules. Since then, yields have climbed steadily, with the record-setting shot in April 2025.
To be clear, this doesn’t mean fusion power plants are around the corner. The lasers themselves consume far more energy than they deliver to the target, so the overall system still uses more power than it generates. But proving that a fusion reaction can produce a significant energy surplus over its input is the foundational step. A separate experiment in June 2025, led by Los Alamos National Laboratory, created what’s called a burning plasma: a self-sustaining feedback loop where the fusion reaction keeps heating itself. That’s the behavior a future power plant would need.
GLP-1 Drugs Are Treating Far More Than Diabetes
Semaglutide and tirzepatide, the drugs behind brand names like Ozempic and Mounjaro, started as diabetes treatments. They’re now generating clinical results across a surprising range of conditions. In the SELECT trial, semaglutide reduced the risk of major cardiovascular events by 20% in people with heart disease and obesity who didn’t have diabetes. The FLOW trial showed a 24% reduction in kidney-related complications for people with diabetes and chronic kidney disease.
The list keeps growing. In the ESSENCE trial, 62.9% of patients taking semaglutide saw resolution of fatty liver disease (MASH) without worsening liver scarring at 72 weeks, compared to 34.3% on placebo. Other trials have shown improvements in heart failure symptoms, knee osteoarthritis pain, and exercise capacity. Tirzepatide, meanwhile, reduced sleep apnea severity by roughly 24 fewer breathing-interruption events per hour compared to placebo.
Perhaps most unexpectedly, real-world data suggests semaglutide may reduce tobacco use, with a 32% lower rate of cessation medication prescriptions (suggesting people needed less help quitting). A phase 2 trial also found it reduced alcohol consumption and cravings in people with alcohol use disorder. These addiction-related findings are early, but they point to effects on the brain’s reward pathways that researchers are still working to understand.
CRISPR Gene Therapy Is Now Treating Patients
In December 2023, the FDA approved the first therapy that uses CRISPR gene editing. Called Casgevy, it treats sickle cell disease in patients 12 and older who experience recurrent pain crises. A second gene therapy, Lyfgenia, was approved the same day for the same condition, though it uses a different technique.
Casgevy works by removing a patient’s blood stem cells, using the CRISPR/Cas9 system to edit their DNA, then transplanting the modified cells back into the bone marrow. The edit boosts production of fetal hemoglobin, a form of hemoglobin that the body normally stops making after infancy. Higher levels of fetal hemoglobin prevent red blood cells from warping into the sickle shape that causes pain and organ damage. It’s a one-time treatment, though the process of harvesting cells, editing them, and transplanting them back is intensive. The significance is less about sickle cell disease alone and more about what it proves: CRISPR can be used safely to treat genetic conditions in humans.
AI Can Now Predict How Molecules Fit Together
AlphaFold, the AI system that stunned biologists in 2020 by predicting protein shapes with near-experimental accuracy, released its third version in 2024. AlphaFold 3 goes well beyond proteins. It can predict the three-dimensional structure of interactions between proteins, DNA, RNA, drug-like small molecules, and the sugar chains that decorate cell surfaces.
This matters because drug development depends on understanding how molecules physically fit together, like keys in locks. Traditionally, determining these structures required months of lab work with specialized equipment. AlphaFold 3 handles proteins, genetic material, and drug compounds within a single system rather than requiring separate tools for each. In one demonstration, it accurately modeled a massive ribosomal complex of over 7,600 amino acid residues, including RNA and protein components. For drug discovery, the ability to predict how a small molecule docks into a protein target could dramatically accelerate the early stages of finding new medicines.
Quantum Error Correction Crossed a Threshold
Quantum computers are famously fragile. Their basic units of information, called qubits, are so sensitive to interference that errors accumulate quickly, limiting what any calculation can accomplish. In 2024, Microsoft and Quantinuum demonstrated a system of four logical qubits (qubits built from groups of physical qubits with built-in error protection) that ran more than 14,000 experiments without a single error. The logical error rate was 800 times better than the error rate of the underlying physical qubits.
The key advance wasn’t just fewer errors. The team also showed they could detect and correct errors on logical qubits without destroying the information stored in them, a process called active syndrome extraction. This is the kind of capability that would need to scale up dramatically before quantum computers can solve problems that classical computers can’t, but crossing the threshold where error correction actually makes things better rather than adding overhead is a genuine turning point.
The Webb Telescope Is Testing Exoplanet Atmospheres
The James Webb Space Telescope has been systematically studying the TRAPPIST-1 system, a group of seven Earth-sized planets orbiting a small star about 40 light-years away. Several of these planets sit in the habitable zone, where liquid water could theoretically exist on the surface. Webb has not yet found definitive signs of an atmosphere on any of them.
The innermost planet, TRAPPIST-1 b, appears to be bare rock. For TRAPPIST-1 e, the planet considered most promising for habitability, researchers have analyzed four transits so far. They’re fairly confident it no longer has its original hydrogen-helium atmosphere, which isn’t surprising given that TRAPPIST-1 is a very active star with frequent flares that would strip away light gases. They also consider it unlikely that the planet has a thick carbon dioxide atmosphere like Venus. Whether it has a thinner, secondary atmosphere (possibly containing water vapor or other heavier gases) remains an open question that more observations could resolve.
2024 Was the Hottest Year on Record
Global surface temperature in 2024 was 1.29°C (2.32°F) above the 20th-century average, according to NOAA. This made 2024 the warmest year in the modern temperature record, surpassing 2023. The spike was partly amplified by an El Niño event, but it sits on top of a clear long-term warming trend driven by greenhouse gas emissions. The 1.29°C figure is notably close to the 1.5°C threshold that international climate agreements have targeted as a limit for avoiding the most severe impacts of climate change.
Two-Million-Year-Old DNA Was Recovered
The oldest DNA ever sequenced comes not from bones but from sediment. Researchers extracted tiny fragments of environmental DNA from geological deposits at Kap København in northern Greenland, dating back two million years into the Pliocene epoch. That’s roughly 800,000 years older than the previous record, which came from mammoth remains.
The DNA revealed an ecosystem nothing like modern Greenland. The area was once forested with willow, birch, and poplar trees, supporting hares, deer, and mastodons. Beyond 78 plant genera already known from fossil evidence at the site, the DNA analysis identified 24 additional genera, painting a far richer picture of what lived there. The finding also suggests that recoverable DNA from even older periods may still be preserved in the right geological conditions.
The World’s Largest Telescope Is Taking Shape
The Extremely Large Telescope, being built by the European Southern Observatory in Chile’s Atacama Desert, passed the halfway mark in construction in 2023. Its primary mirror will be composed of 798 hexagonal segments working together as a single surface 39 meters across, dwarfing every existing optical telescope. The telescope structure is expected to be complete by late 2026, the dome by early 2027, and first test observations are planned for early 2029. Scientific observations using its full instrument suite should begin by December 2030. The ELT will be powerful enough to directly image exoplanets and analyze their atmospheres, complementing the work Webb is doing from space with ground-based observations at far higher resolution.
Room-Temperature Superconductivity Didn’t Pan Out
In mid-2023, a team of South Korean researchers claimed to have created LK-99, a material that superconducts at room temperature and ambient pressure. If true, it would have been one of the most important discoveries in physics, enabling lossless power transmission, revolutionary electronics, and levitating transport. The claim went viral, and labs worldwide rushed to replicate it. Within about two weeks, the consensus was clear: LK-99 is not a room-temperature superconductor. Multiple independent replication studies, later published in peer-reviewed journals, showed that the unusual electrical and magnetic properties the original team observed were caused by impurities in the material, not superconductivity. The episode became a useful case study in how quickly modern science can test extraordinary claims.